Skip to main content
SpringerLink
Log in

Donepezil in Treatment of AD

  • Chapter
Alzheimer’s Disease

Part of the book series: Current Clinical Neurology ((CCNEU))

  • 350 Accesses

Abstract

Donepezil is the second cholinesterase inhibitor to have become commercially available. It is considered a “second-generation” acetylcholinesterase inhibitor (AChEI) because of its safety profile with clear advantages over the acridine-based cholinesterase inhibitor tacrine, the first AChEI approved for symptomatic treatment of Alzheimer’s disease (AD). Because of considerable toxicity, tacrine is no longer used since the advent of the second generation of AChEIs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Dooley, M.; Lamb, H.M.: Donepezil: a review of its use in Alzheimer’s disease. Drugs Aging 2000; 16: 199–226.

    Article  PubMed  CAS  Google Scholar 

  2. Rogers, S.L. et al.: Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998; 158: 1021–1031.

    Article  PubMed  CAS  Google Scholar 

  3. Barner, E.L.; Gray, S.L.: Donepezil use in Alzheimer disease. Ann Pharmacother 1998; 32: 70–77.

    Article  PubMed  CAS  Google Scholar 

  4. Rogers, S.L. et al.: Pharmacokinetics and pharmacodynamic profile of donepezil HC1 following multiple oral dose. Br J Clin Pharmacol 1998; 46: 7–12.

    Article  PubMed  CAS  Google Scholar 

  5. Jann, M.W.; Shirley, K.L.; Small, G.W: Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002; 41: 719–739.

    Article  PubMed  CAS  Google Scholar 

  6. Burns, A. et al.: The effects of donepezil in Alzheimer’s disease results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237–244.

    Article  PubMed  CAS  Google Scholar 

  7. Feldman, H. et al.: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001; 57: 613–620.

    Article  PubMed  CAS  Google Scholar 

  8. Rogers, S.L.; Friedhoff, L.T.: The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 1996; 7: 293–303.

    PubMed  CAS  Google Scholar 

  9. Rogers, S.L. et al.: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology 1998; 50: 136–145.

    Article  PubMed  CAS  Google Scholar 

  10. Homma, A. et al.: Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer’s disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord 2000; 11: 299–313.

    Article  PubMed  CAS  Google Scholar 

  11. Mohs, R.C. et al.: A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481–488.

    Article  PubMed  CAS  Google Scholar 

  12. Greenberg, S.M. et al.: Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol 2000; 57: 94–99.

    Article  PubMed  CAS  Google Scholar 

  13. Tariot, P.N et al.: A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc 2001; 49: 1590–1599.

    Article  PubMed  CAS  Google Scholar 

  14. Winblad, B. et al.: A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489–495.

    Article  PubMed  CAS  Google Scholar 

  15. Rosen, W.G.; Mohs, R.C.; Davis, K.L.: A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984; 141: 1356–1364.

    PubMed  CAS  Google Scholar 

  16. Schneider, L.S. et al.: Validity and reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer’s Disease Cooperative Study. Alzheimer’s Dis Assoc Disord 1997; 11: S22 - S32.

    Article  Google Scholar 

  17. Berg, L. et al.: Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention. Ann Neurol 1992; 31: 242–249.

    Article  PubMed  CAS  Google Scholar 

  18. Guy, W.: Clinical global impressions (CGI). In Guy, W. (ed.), ECDEU assessment manual for psychopharmacology, revised. Alcohol Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD, 1976.

    Google Scholar 

  19. Blessed, G.; Tomlinson, B.E.; Roth, M.: The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968; 114: 797–811.

    Article  PubMed  CAS  Google Scholar 

  20. Lawton, M.P.; Brody, E.M.: Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 179–186.

    Article  PubMed  CAS  Google Scholar 

  21. Schmeidler, J.; Mohs, R.C.; Aryan, M.: Relationship of disease severity to decline on specific cognitive and functional measures in Alzheimer disease. Alzheimer’s Dis Assoc Disord 1998; 12: 146–151.

    Article  CAS  Google Scholar 

  22. Morris, J.C.: The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412–2414.

    Article  PubMed  CAS  Google Scholar 

  23. Gottfries, C.G. et al.: A new rating scale for dementia syndromes. Arch Gerontol Geriatr 1982; 1: 311–330.

    Article  PubMed  CAS  Google Scholar 

  24. Brâne, G.; Gottfries, C.G.; Winblad, B.: The Gottfries-Brâne-Steen scale: validity, reliability and application in anti-dementia drug trials. Dement Geriatr Cogn Disord 2001; 12: 1–14.

    Article  PubMed  Google Scholar 

  25. Panisset, M. et al.: Severe impairment battery. A neuropsychological test for severely demented patients. Arch Neurol 1994; 51: 41–45.

    Article  PubMed  CAS  Google Scholar 

  26. Gélinas, I. et al.: Development of a functional measure for persons with Alzheimer’s disease: the disability assessment for dementia. Am J Occup Ther 1999; 53: 471–481.

    Article  PubMed  Google Scholar 

  27. Cummings, J.L. et al.: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308–2314.

    Article  PubMed  CAS  Google Scholar 

  28. Wood, S. et al.: The use of the neuropsychiatric inventory in nursing home residents. Characterization and measurement. Am J Geriatr Psychiatry 2000; 8: 75–83.

    Article  PubMed  CAS  Google Scholar 

  29. Doody, R.S. et al.: Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001; 58: 427–433.

    Article  PubMed  CAS  Google Scholar 

  30. McRae, T. et al.: Donepezil delays time to nursing home placement in patients with Alzheimer’s disease. J Am Geriatr Soc 2001; 49: 132.

    Google Scholar 

  31. Lopez, O.L. et al.: Cholinesterase inhibitor treatment alters the natural history of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2002; 72: 310–314.

    Article  PubMed  CAS  Google Scholar 

  32. Small, G.W.; Donohue, 7.A.; Brooks, R.L.: An economic evaluation of donepezil in the treatment of Alzheimer’s disease. Clin Ther 1998; 20: 838–850.

    Article  PubMed  CAS  Google Scholar 

  33. Wimo, A. et al.: An economic evaluation of donepezil in mild to moderate Alzheimer’s disease: results of a 1-year, double-blind, randomized trial. Dement Geriatr Cogn Disord 2003; 15: 44–54.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Ging-Yuek Robin Hsiung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Howard Feldman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The University of Oklahoma College of Medicine, USA

    Ralph W. Richter MD, FACP (Clinical Professor of Neurology and Psychiatry, Director) (Clinical Professor of Neurology and Psychiatry, Director)

  2. Alzheimer’s Disease Research Unit, St. John Medical Center, Tulsa, OK, USA

    Ralph W. Richter MD, FACP (Clinical Professor of Neurology and Psychiatry, Director) (Clinical Professor of Neurology and Psychiatry, Director)

  3. Tulsa, OK, USA

    Brigitte Zoeller Richter DiplPharm (Pharmacist, Publicist) (Pharmacist, Publicist)

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Hsiung, GY.R., Feldman, H. (2004). Donepezil in Treatment of AD. In: Richter, R.W., Richter, B.Z. (eds) Alzheimer’s Disease. Current Clinical Neurology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-661-4_20

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-661-4_20

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-4485-9

  • Online ISBN: 978-1-59259-661-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation